The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis – an introduction

References

• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1-233
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom. A population-based study. Arch Dermatol 2005;141:1537-41
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2009;60:643-59
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31-6
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-34
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Fanti PA, Orlandi C, et al. Psoriatic scarring alopecia: observations in four patients. Int J Dermatol 1999;38:765-8
   PubMed Web of Science ®Google Scholar
• Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-7
   Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
   PubMed Web of Science ®Google Scholar
• Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7
   PubMed Web of Science ®Google Scholar
• Chan CS, van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Am Acad Dermatol 2009;60:962-71
   PubMed Web of Science ®Google Scholar
• Skincare Conditions in Scotland: What the Healthcare Professionals think. A report of a survey of service provision for patients with dermatological conditions. October 2008. SSCIG, The Scottish Skincare Conditions Industry Group. Available at: http://www.abpi.org.uk/Scotland/pdf/SSCIGSurveyFinalReportOct08.pdf [Accessed on 18 June 2010]
   Google Scholar
• Department of Health. Hospital Episode Statistics. L40 Psoriasis. HESonline primary diagnosis: 3 character 2008-2009. Diagnosis3_0709.xls. Available at http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=203 [Accessed 8 June 2010]
   Google Scholar
• Department of Health. National Schedule of Reference Costs. Elective inpatient HRG Data. Weighted average unit cost of currency codes JD02A, JD02B, JD02C (major skin disorder Category 1 with major CC, with intermediate CC, without CC, respectively). PBR_2007-08_NSRC04.xls available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945 [Accessed 10 June 2010]
   Google Scholar
• Eedy DJ, Wootton R. Teledermatology: a review. Br J Dermatology 2001;144:696-707
   PubMed Web of Science ®Google Scholar
• Suneja T, Smith ED, Chen GJ, et al. Waiting times to see a dermatologist are perceived as too long by dermatologists. Implications for the dermatology workforce. Arch Dermatol 2001;137:1303-7
   PubMed Web of Science ®Google Scholar
• Cherry DK, Burt CW, Woodwell DA. National ambulatory medical care survey: 1999 Summary. Advance data [From vital and health statistics] 2001;322:1-36
   Google Scholar
• Thompson TT, Feldman SR, Fleischer AB Jr. Only 33% of visits for skin disease in the US in 1995 were to dermatologists: is decreasing the number of dermatologists the appropriate response? Dermatol Online 1998;4:3
   PubMedGoogle Scholar
• Uttjek M, Dufåker M, Stenberg B, et al. Priority dilemmas in psoriasis care and visions of a future care in a group of administrators, politicians and professionals in northern Sweden. Health Policy 2008;87:203-16
   PubMed Web of Science ®Google Scholar
• Atopic eczema, psoriasis and acne: common chronic skin conditions that constitute a burden to general practice. A briefing paper prepared by Professor Carol Black, Professor David Gawkrodger and Dr Mark Goodfield on behalf of the Joint Specialty Committee for Dermatology. 14 February 2005. Available at: http://www.skincarecampaign.org/pages/SkinCareCampaignPolicy.htm [Accessed 10 June 2010]
   Google Scholar
• Imison C, Naylor C. Referral management. Lessons for success. 12 August 2010. The Kings Fund. Available at http://www.kingsfund.org.uk/publications/referral_management.html (Accessed 18 August 2010)
   Google Scholar
• NICE. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. July 2006. Available at http://guidance.nice.org.uk/TA103/Guidance/pdf/English [last accessed 19 September 2010]
   Google Scholar
• Equity and excellence: liberating the NHS. UK Coalition Government White Paper available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117353 [Accessed 19 September 2010]
   Google Scholar
• Porter ME. A strategy for health care reform – toward a value-based system. N Engl J Med 2009;10.1056/NEJMpo904131
   Google Scholar
• Oh, PI, Gupta AK, Einarson TR, et al. Calcipotriol in the treatment of psoriasis of limited severity: pharmacoeconomic evaluation. J Cutan Med Surg 1997;2:7-15
   Google Scholar
• Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild to moderate stable plaque psoriasis: a US study. Clin Ther 1998;20:851-69
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Po AL, Williams HC, et al. Cost effectiveness analysis of topical calcipotriol versus short-contact dithranol. Pharmacoeconomics 2000;18:469-76
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007;23:1887-901
   PubMed Web of Science ®Google Scholar
• Freeman K, Marum M, Bottomley JM, et al. A psoriasis-specific model to support decision-making in practice – UK experience. Curr Med Res Opin 2011;27:205-23
   Google Scholar
• Van de Kerkhof P, de Peuter R, Ryttov J, et al. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin 2011;27:225-38
   Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-35
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PCM, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate once or twice daily compared to calcipotriol twice daily in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation Daivobet is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-73
   PubMed Web of Science ®Google Scholar
• Papp K, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-83
   PubMed Web of Science ®Google Scholar
• Zaghloul S, Goodfield M. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-14
   PubMed Web of Science ®Google Scholar
• van der Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65
   PubMedGoogle Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Myles JP, Jones DR, et al. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 1999;319:508-12
   PubMed Web of Science ®Google Scholar
• Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 2000;43:281-85
   PubMed Web of Science ®Google Scholar
• Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005;141:82-84
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38
   PubMed Web of Science ®Google Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li W, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-67
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Chimenti S, Luger T, et al. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 2009;23:1435-44
   PubMed Web of Science ®Google Scholar
• Recommendations for the initial management of psoriasis. British Association of Dermatologists and Primary Care Dermatology Society. Guidelines 2009;39:395-6. Available at http://www.eGuidelines.co.uk [Accessed 18 June 2010]
   Google Scholar
• Smith DRW, Bottomley JM, Auland M, et al. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish Health professionals. Curr Med Res Opin 2011;27:239-49
   Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: A systematic review of direct and indirect evidence. Curr Med Res Opin 2011;27:251-68
   Google Scholar
• Affleck AG, Bottomley JM, Auland ME, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:269-84
   Google Scholar
• Scottish Medicines Consortium. Calcipotriol and betamethasone dipropionate, 50 micrograms/g + 500 microgram/g gel (Xamiol®). No. 559/09. 10 July 2009. Available at http://www.scottishmedicines.org/smc/files/Microsoft%20Word%20-%20calcipotriol%20and%20betamethasone%20dipropionate%20_Xamiol_%20FINAL%20July%202009%20for%20website.pdf [Accessed on 19 September 2010]
   Google Scholar
• NICE Guide to the methods of technology Appraisal (NICE June 2008). Available at http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed on 19 September 2010]
   Google Scholar
• Øvretveit J. Does improving quality save money? A review of evidence of which improvements to quality reduce costs to health service providers. Internet document September 2009: Available from URL: http://www.health.org.uk/publications/research_reports/does_quality_save.html [Accessed 19 September 2010]
   Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. [online];Available from: http://www.nice.org.uk
   Google Scholar
• Urdahl H, Manca A, Sculpher MJ. Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis. PharmacoEconomics 2006;24:1181-97
   PubMed Web of Science ®Google Scholar
• Manca A and Willan AR. ‘Lost in translation’. Accounting for between-Country differences in the analysis of multinational cost-effectiveness data. PharmacoEconomics 2006;24:1101-19
   PubMed Web of Science ®Google Scholar
• Goeree R, Burke N, O’Reilly DO, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23:671-82
   PubMed Web of Science ®Google Scholar